Drug
Rhigf I Rhigfbp 3
Rhigf I Rhigfbp 3: highest development phase Phase 2/3, developed by Insmed. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2/3
- Developer
- Insmed
Trials
| Drug | Phase | Indication |
|---|---|---|
| rhIGF-I/rhIGFBP-3 NCT00368173 | Phase 2/3 | Growth Hormone Insensitivity Syndrome (GHIS) |
Latest
No recent events.
Follow Rhigf I Rhigfbp 3 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.